MedPath

bivalirudin

These highlights do not include all the information needed to use BIVALIRUDIN FOR INJECTION safely and effectively. See full prescribing information for BIVALIRUDIN FOR INJECTION. Initial U.S. Approval: 2000

Approved
Approval ID

5d9a45c6-e234-4d56-9132-5e24e65852e6

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 9, 2021

Manufacturers
FDA

Slate Run Pharmaceuticals, LLC

DUNS: 039452765

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

bivalirudin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70436-025
Application NumberANDA213078
Product Classification
M
Marketing Category
C73584
G
Generic Name
bivalirudin
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJune 9, 2021
FDA Product Classification

INGREDIENTS (3)

MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
BIVALIRUDINActive
Quantity: 250 mg in 1 1
Code: TN9BEX005G
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

bivalirudin - FDA Drug Approval Details